Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG in Painful Sensory Neuropathy
NCT06183008Phase 4Not yet recruiting
- Sponsor
- Sørlandet sykehus
- Start
- Feb 2024
- Primary completion
- Dec 2028
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, double-blind trial in Painful sensory neuropathy (PSN), small fiber neuropathy (SFN) and sensory neuronopathy (SNN) comparing Intravenous Immunoglobulin with Placebo (2 arms). Primary endpoint: Pain intensity the second week at Week 2. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Painful sensory neuropathy (PSN)small fiber neuropathy (SFN)sensory neuronopathy (SNN)
Beyond the preview
Go deeper on NCT06183008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06183008.